[go: up one dir, main page]

WO2007020502A3 - Cannabinoid receptor ligands and uses thereof - Google Patents

Cannabinoid receptor ligands and uses thereof Download PDF

Info

Publication number
WO2007020502A3
WO2007020502A3 PCT/IB2006/002172 IB2006002172W WO2007020502A3 WO 2007020502 A3 WO2007020502 A3 WO 2007020502A3 IB 2006002172 W IB2006002172 W IB 2006002172W WO 2007020502 A3 WO2007020502 A3 WO 2007020502A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor ligands
cannabinoid receptor
cannabinoid
mediation
animals
Prior art date
Application number
PCT/IB2006/002172
Other languages
French (fr)
Other versions
WO2007020502A2 (en
Inventor
Philip Albert Carpino
Mark Allen Sanner
Original Assignee
Pharmacia & Upjohn Co Llc
Philip Albert Carpino
Mark Allen Sanner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc, Philip Albert Carpino, Mark Allen Sanner filed Critical Pharmacia & Upjohn Co Llc
Publication of WO2007020502A2 publication Critical patent/WO2007020502A2/en
Publication of WO2007020502A3 publication Critical patent/WO2007020502A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2732-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.
PCT/IB2006/002172 2005-08-16 2006-08-04 Cannabinoid receptor ligands and uses thereof WO2007020502A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70904505P 2005-08-16 2005-08-16
US60/709,045 2005-08-16

Publications (2)

Publication Number Publication Date
WO2007020502A2 WO2007020502A2 (en) 2007-02-22
WO2007020502A3 true WO2007020502A3 (en) 2007-04-19

Family

ID=37605675

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/002172 WO2007020502A2 (en) 2005-08-16 2006-08-04 Cannabinoid receptor ligands and uses thereof

Country Status (1)

Country Link
WO (1) WO2007020502A2 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008014199A2 (en) 2006-07-28 2008-01-31 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 receptor
JP2010500300A (en) 2006-08-08 2010-01-07 サノフィ−アベンティス Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for their preparation, agents containing these compounds, and uses thereof
EA200900403A1 (en) 2006-09-25 2009-10-30 Бёрингер Ингельхайм Интернациональ Гмбх COMPOUNDS WHICH MODULATE CB2 RECEPTOR
CL2007003002A1 (en) * 2006-10-23 2008-06-06 Eli Lilly And Company Soc Oran COMPOUND 3- [1-METHYL-1- (6-TRIFLUOROMETIL-PIRIDIN-3-IL) -ETILAMINO] -5- (3-TRIFLUOROMETOXIFENIL) -1- (4-TRIFLUOROMETIL-PHENYL) -PIRROLIDIN-2-ONA; AND USE FOR THE TREATMENT OF A SELECTED OBESITY DISORDER, SCHIZOPHRENIA, SUBSTANCE ABUSE OR DEPENDS
TW200831080A (en) 2006-12-15 2008-08-01 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2008112674A1 (en) * 2007-03-12 2008-09-18 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2008121065A1 (en) * 2007-03-30 2008-10-09 Astrazeneca Ab Novel pyrrolidine derivatives as antagonists of the chemokine receptor
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
WO2009061652A1 (en) 2007-11-07 2009-05-14 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
SI2963031T1 (en) 2007-11-30 2019-04-30 Zynerba Pharmaceuticals, Inc. Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same
SI2280961T1 (en) * 2008-04-22 2012-11-30 Lilly Co Eli 1,5-diphenyl-pyrrolidin-2-one compounds as cb-1 ligands
CN102119029B (en) * 2008-04-22 2013-03-13 伊莱利利公司 1,5-Diphenyl-pyrrolidin-2-one compounds as CB-1 ligands
EP2310372B1 (en) 2008-07-09 2012-05-23 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
EP2326629B1 (en) * 2008-07-10 2013-10-02 Boehringer Ingelheim International GmbH Sulfone compounds which modulate the cb2 receptor
KR20110063485A (en) 2008-09-25 2011-06-10 베링거 인겔하임 인터내셔날 게엠베하 Sulfonyl Compounds Selectively Modulate CB2 Receptors
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
EP2443107B1 (en) 2009-06-16 2018-08-08 Boehringer Ingelheim International GmbH Azetidine 2 -carboxamide derivatives which modulate the cb2 receptor
PT2470552E (en) 2009-08-26 2014-01-30 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011037795A1 (en) 2009-09-22 2011-03-31 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the cb2 receptor
JP2013517271A (en) 2010-01-15 2013-05-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Compounds that modulate the CB2 receptor
EP2542539B1 (en) 2010-03-05 2014-02-26 Boehringer Ingelheim International GmbH Tetrazole compounds which selectively modulate the cb2 receptor
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
WO2012012307A1 (en) 2010-07-22 2012-01-26 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 rece
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (en) 2011-03-08 2016-06-01 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
CN104788357B (en) * 2014-01-16 2017-06-06 韶远科技(上海)有限公司 The one class industrialized synthesis technique of chiral amino lactam compound
CN120398799B (en) * 2025-06-27 2025-09-30 浙江海洋大学 A sponge-derived polyketolactone enantiomer and its preparation method and application

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003027069A1 (en) * 2001-09-24 2003-04-03 Bayer Pharmaceuticals Corporation Preparation and use of pyrrole derivatives for treating obesity
WO2004058249A1 (en) * 2002-12-24 2004-07-15 Astrazeneca Ab 1,5-diaryl-pyrrole-3-carboxamide derivatives and their use as cannabinoid receptor modulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003027069A1 (en) * 2001-09-24 2003-04-03 Bayer Pharmaceuticals Corporation Preparation and use of pyrrole derivatives for treating obesity
WO2004058249A1 (en) * 2002-12-24 2004-07-15 Astrazeneca Ab 1,5-diaryl-pyrrole-3-carboxamide derivatives and their use as cannabinoid receptor modulators

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; VAUGHAN, WYMAN R. ET AL: "2,3-Pyrrolidinediones. III. Tautomeric rearrangement", XP002416211, retrieved from STN Database accession no. 1954:18295 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; WASSERMAN, HARRY H. ET AL: "1,5-Diphenyl-2,3-pyrrolidinedione and related compounds", XP002416210, retrieved from STN Database accession no. 1962:416837 *
DUGAR, SUNDEEP ET AL: "Gamma-lactams and related compounds as cholesterol absorption inhibitors: homologs of the beta-lactam cholesterol absorption inhibitor SCH 48461", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS , 5(24), 2947-52 CODEN: BMCLE8; ISSN: 0960-894X, 1995, XP002415223 *
JOURNAL OF ORGANIC CHEMISTRY , 18, 405-21 CODEN: JOCEAH; ISSN: 0022-3263, 1953 *
JOURNAL OF ORGANIC CHEMISTRY , 27, 35-9 CODEN: JOCEAH; ISSN: 0022-3263, 1962 *
PELLETIER, JEFFREY C. ET AL: "Preparation of highly substituted .gamma.-lactam follicle stimulating hormone receptor agonists", BIOORGANIC & MEDICINAL CHEMISTRY , 13(21), 5986-5995 CODEN: BMECEP; ISSN: 0968-0896, 2005, XP002415222 *

Also Published As

Publication number Publication date
WO2007020502A2 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
WO2007020502A3 (en) Cannabinoid receptor ligands and uses thereof
MXPA05007938A (en) Cannabinoid receptor ligands and uses thereof.
TW200503723A (en) Cannabinoid receptor ligands and uses thereof
TW200510419A (en) Cannabinoid receptor ligands and uses thereof
MXPA05011362A (en) Cannabinoid receptor ligands and uses thereof.
MXPA05013294A (en) Cannabinoid receptor ligands and uses thereof.
TW200714603A (en) Acylaminobicyclic heteroaromatic compounds and uses thereof
MXPA05013282A (en) Pyrimidine derivatives as cannabinoid receptor ligands.
MXPA05011922A (en) Cannabinoid receptor ligands and uses thereof.
MY140010A (en) Purine compounds and use thereof as cannabinoid receptor ligands
MXPA05007562A (en) Pyrazolo`1,5-a!`1,3,5!triazine derivatives as cannabinoid receptor ligands.
UA74443C2 (en) 5-HT receptor ligands and their use
EA200501430A1 (en) Cannabinoid receptor ligands and their use
WO2009002947A3 (en) Compounds and peptides that bind the trail receptor
EA200600647A1 (en) COMPOUNDS OF BICYCLIC PYRAZOLYL AND IMIDAZOLYL AND THEIR APPLICATION
WO2007021937A3 (en) Unsaturated heterocyclic derivatives
WO2007044085A3 (en) Heteroaryl compounds and their uses as therapeutic agents
MX2007005205A (en) Sulfonyl-substituted bicyclic compounds as modulators of ppar.
TW200745043A (en) Substituted pyrazoline compounds, their preparation and use as medicaments
MX2009005358A (en) 5-sulfanylmethyl-pyrazolo [1,5-a] pyrimidin-7-ol derivatives as cxcr2 antagonists.
WO2007072201A3 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
WO2009071689A3 (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
WO2006004684A3 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
WO2007098964A3 (en) Pyrrazole derivatives as sigma receptors antagonists
WO2007047431A3 (en) Sulfonyl-substituted aryl compounds as modulators of peroxisome proliferator activated receptors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06779949

Country of ref document: EP

Kind code of ref document: A2